Drug Profile
Rupitasertib - Evexta Bio
Alternative Names: DIACC-3010; M-2698; MSC-2363318ALatest Information Update: 17 Jan 2024
Price :
$50
*
At a glance
- Originator EMD Serono
- Developer EMD Serono; Evexta Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 positive breast cancer; Solid tumours
- Preclinical Gastric cancer; Glioblastoma
Most Recent Events
- 17 Jan 2024 Preclinical trials in Glioblastoma in France (PO) (Evesta Bio pipeline January 2024) (Prior to January 2024)
- 04 Jan 2024 Diaccurate is now called Evexta Bio
- 01 Jun 2023 Phase-I development is ongoing in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO) (Diaccurate pipeline; June 2023)